Global optimization-based inference of chemogenomic features from drug-target interactions

Bioinformatics

Volumn 31, Issue 15, 2015, Pages 2523-2529

  Zu, Songpeng ^a   Chen, Ting ^a,b   Li, Shao ^a  

^a TSINGHUA UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; PROTEIN; PROTEIN BINDING;

ALGORITHM; CHEMISTRY; DATA MINING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG REPOSITIONING; FACTUAL DATABASE; HUMAN; METABOLISM; PROCEDURES; PROTEIN DOMAIN; PROTEIN TERTIARY STRUCTURE;

ALGORITHMS; DATA MINING; DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG REPOSITIONING; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, TERTIARY; PROTEINS;

EID: 84943620492     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btv181     Document Type: Article

References (32)

1. Bateman, A. et al. (2004) The Pfam protein families database. Nucleic Acids. Res., 32, D138-D141.
2. Bemis, G. W. et al. (1996) The properties of know drugs.1. Molecular frameworks. J. Med. Chem., 39, 2887-2893.
3. Bredel, M. and Jacoby, E. (2004) Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet., 5, 262-275.
4. Berman, H. M. et al. (2000) The protein data bank. Nucleic Acids Res., 28, 235-242.
5. Chothia, C. (1984) Principles that determine the structure of proteins. Annu. Rev. Biohem., 53, 537-572.
6. Deng, M. et al. (2002) Inferring domain-domain interactions from protein-protein interactions. Genome Res., 12, 1540-1548.
7. De Beer, T. A. et al. (2014) PDBsum additions. Nucleic Acids. Res., 42, D292-D296.
8. Dempster, A. P. et al. (1977) Maximum likelihood from incomplete data via the EM algorithm. J. R. Stat. Soc. Series. B., 39, 1-38.
9. Duran-Frigola, M. and Aloy, P. (2013) Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem. Biol. 20, 594-603.
10. Efron, B. et al. (1978) Assessing the accuracy of the maximum likelihood estimator: Observed versus expected Fisher information. Biometrika, 65, 457-483.
11. Gallina, A. M. et al. (2013) PLI: a web-based tool for the comparison of protein-ligand interactions observed on PDB structures. Bioinformatics, 29, 395-397.
12. Gaulton, A. et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 40, D1100-D1107.
13. Geman, S. et al. (1984) Stochastic relaxation, Gibbs distribution, and the Bayesian restoration of images. IEEE Trans. Pattern Anal. Mach. Intell., 23, 97-115.
14. Koehn, F. E. and Carter G. T. (2005) The evolving role of natural products in drug discovery, Nat. Rev. Drug Discov., 4, 206-220.
15. Kruger, F. A. et al. (2012) Mapping small molecule binding data to structural domains. BMC Bioinformatics, 13, S11.
16. Kruger, F. A. et al. (2014) PPDMs-a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains. Bioinformatics, 31, 776-778.
17. Magoulas, G. E. et al. (2011) Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part. Eur. J. Med. Chem., 46, 721-737.
18. Mestres, J. et al. (2008) Data completeness-the Achilles heel of drug-target networks, Nat. Biotechnol., 26, 983-984.
19. Murray, C. W. and Rees, D. C. (2009) The rise of fragment-based drug discovery, Nat. Chem., 1, 187-192.
20. Ocker, M. et al. (2004) Potentiated anticancer effects on hepatoma cells by the retinoid adapalene. Cancer Lett., 208, 51-58.
21. So, P. L. et al. (2014) PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. Cancer Prev. Res., 7, 407-417.
22. Sousa, S. F. et al. (2013) Protein-ligand docking in the new millennium-a restrospective of 10 years in the field. Curr. Med. Chem., 20, 2296-2314.
23. Tabei, Y. et al. (2012) Identification of chemogenomic features from drug-target interaction networks using interpretable classifiers. Bioinformatics, 28, i487-i494.
24. Takigawa, I. et al. (2011) Mining significant substructure pairs for interpreting polypharmacology in drug-target network. PloS One, 6, e16999.
25. Vogel, V. G. et al. (2010) Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev. Res., 3, 696-706.
26. Wang, Y. et al. (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids. Res., 37, W623-W633.
27. Wallace, AC. et al. (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng., 8, 127-134.
28. Wishart, D. S. et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids. Res., 36, D901-D906.
29. Yabuuchi, H. et al. (2011) Analysis of multiple compound-protein interactions reveals novel bioactive molecules. Mol. Syst. Biol., 7, 472.
30. Yamanishi, Y. et al. (2011) Extracting sets of chemical substructures and protein domains governing drug-target interactions. J. Chem. Inf. Model., 51, 1183-1184.
31. Yang, J. et al. (2013) Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinformatics, 29, 2588-2595.
32. Zhao, S. and Li, S. (2010) Network-based relating pharmacological and genomic spaces for drug target identification. Plos One, 5, e11764.